Augmented high-dose regimen of cyclophosphamide, carmustine, and etoposide with autologous hematopoietic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphoma

References

• Harris N L, Jaffee E S, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• World health organization classification of tumours: pathology and genetics of tumors of haematopoietic and lymphoid tissues, E S Jaffe, N L Harris, H Stein. IARC Press, Lyon 2001
   Google Scholar
• Armitage J O, Weisenburger D D. New approach to classifying the non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. J Clin Oncol 1998; 16: 2780–2795
   PubMed Web of Science ®Google Scholar
• Wheeler C, Strawderman M, Ayash L, et al. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide. J Clin Oncol 1993; 11: 1085–1091
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Stockerl-Goldstein K E, Horning S J, Negrin R S, et al. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 1996; 2: 76–85
   PubMedGoogle Scholar
• Rapaport A P, Lifton R, Constine L S, et al. Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma: long-term follow-up and analysis of prognostic factors. Bone Marrow Transplant 1997; 19: 883–890
   PubMed Web of Science ®Google Scholar
• Stiff P J, Dahlberg S, Forman S J, et al. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens-a Southwest Oncology Group Trial. J Clin Oncol 1998; 16: 48–55
   PubMed Web of Science ®Google Scholar
• Guglielmi C, Gomez F, Philip T, et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma Trial. J Clin Oncol 1998; 16: 3264–3269
   PubMed Web of Science ®Google Scholar
• Stein R S, Greer J P, Goodman S, et al. Intensified preparative regimens and autologous transplantation in relapsed and refractory intermediate grade non-Hodgkin's lymphoma. Bone Marrow Transplant 2000; 25: 257–262
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Zelenetz A D, Hedrick E E, et al. High-dose therapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin's lymphoma: an intention-to-treat analysis. Blood 2000; 96: 2399–2404
   PubMed Web of Science ®Google Scholar
• Vose J M, Zhang M -J, Rowlings P A, et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001; 19: 406–413
   PubMed Web of Science ®Google Scholar
• Bolwell B, Kalaycio M, Sobecks R, et al. Autologous hematopoietic cell transplantation for non-Hodgkin's lymphoma: 100 month follow-up. Bone Marrow Transplant 2002; 29: 673–679
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244–1253
   PubMed Web of Science ®Google Scholar
• Surbone A, Longo D L, DeVita-Jr V T, et al. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management. J Clin Oncol 1988; 1832–1837
   PubMed Web of Science ®Google Scholar
• Robertson M J, Pelloso D, Abonour R, et al. Interleukin-12 immunotherapy after autologous stem cell transplantation for hematologic malignancies. Clin Cancer Res 2002; 8: 3383–3393
   PubMed Web of Science ®Google Scholar
• Stamatoullas A, Fruchart C, Khalfallah S, et al. Peripheral blood stem cell transplantation for relapsed or refractory lymphoma in patients over 60 years of age. Bone Marrow Transplant 1997; 19: 31–35
   PubMed Web of Science ®Google Scholar
• Olivieri A, Capelli D, Montanari M, et al. Very low toxicity and good quality of life in 48 elderly patients autotransplanted for hematological malignancies: a single center experience. Bone Marrow Transplant 2001; 27: 1189–1195
   PubMed Web of Science ®Google Scholar
• Gopal A K, Gooley T A, Golden J B, et al. Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older. Bone Marrow Transplant 2001; 27: 593–599
   PubMed Web of Science ®Google Scholar
• Schouten H C, Bierman P J, Vaughan W P, et al. Autologous bone marrow transplantation in follicular non-Hodgkin's lymphoma before and after histologic transformation. Blood 1989; 74: 2579–2584
   PubMed Web of Science ®Google Scholar
• Freedman A S, Takvorian T, Anderson K C, et al. Autologous bone marrow transplantation in B-cell non-Hodkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse. J Clin Oncol 1990; 8: 784–791
   PubMed Web of Science ®Google Scholar
• Bastion Y, Brice P, Haioun C, et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 1995; 86: 3257–3262
   PubMed Web of Science ®Google Scholar
• Chen C I, Crump M, Tsang R, et al. Autotransplants for histologically transformed non-Hodgkin's lymphoma. Br J Haematol 2001; 113: 202–208
   PubMed Web of Science ®Google Scholar
• Shipp M A, Abeloff M D, Antman K H, et al. International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. J Clin Oncol 1999; 17: 423–429
   PubMed Web of Science ®Google Scholar
• Philip T, Armitage J O, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987; 316: 1493–1498
   PubMed Web of Science ®Google Scholar
• Phillips G L, Reece D E, Wolff S N, et al. The use of conventional salvage chemotherapy before dose-intensive cytotoxic therapy and autologous transplantation for agressive-histology lymphoma: a case for re-evaluation. Leuk Lymphoma 1997; 26: 507–513
   PubMed Web of Science ®Google Scholar
• Leonard B M, Hetu F, Busque L, et al. Lymphoma cell burden in progenitor cell grafts measured by competitive polymerase chain reaction: less than one log difference between bone marrow and peripheral blood sources. Blood 1998; 91: 331–339
   PubMed Web of Science ®Google Scholar
• McCann J C, Kanteti R, Shilepsky B, et al. High degree of occult tumor contamination in bone marrow and peripheral blood stem cells of patients undergoing autologous transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 1996; 2: 37–43
   PubMedGoogle Scholar
• Sharp J G, Kessinger A, Mann S, et al. Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. J Clin Oncol 1996; 14: 214–219
   PubMed Web of Science ®Google Scholar
• Sharp J G, Joshi S S, Armitage J O, et al. Significance of detection of occult non-Hodgkin's lymphoma in histologically uninvolved marrow by a culture technique. Blood 1992; 79: 1074–1080
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Lepage E, Molina T, et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002; 20: 2472–2479
   PubMed Web of Science ®Google Scholar
• Williams C D, Goldstone A H, Pearce R M, et al. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. J Clin Oncol 1996; 14: 2454–2464
   PubMed Web of Science ®Google Scholar
• Singhal S, Powles R, Treleaven J, et al. A low CD34 + cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 x 10(6) CD34 + cells/kg be considered the minimum threshold?. Bone Marrow Transplant 2000; 26: 489–496
   PubMed Web of Science ®Google Scholar
• Davies S M, Kollman C, Anasetti C, et al. Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the National Marrow Donor Program. Blood 2000; 96: 4096–4102
   PubMed Web of Science ®Google Scholar
• Dominietto A, Lamparelli T, Raiola A M, et al. Transplant-related mortality and long-term graft function are significantly influenced by cell dose in patients undergoing allogeneic marrow transplantation. Blood 2002; 100: 3930–3934
   PubMed Web of Science ®Google Scholar
• Ketterer N, Salles G, Raba M, et al. High CD34 + cell counts decrease hematologic toxicity after autologous peripheral blood progenitor cell transplantation. Blood 1998; 91: 3148–3155
   PubMed Web of Science ®Google Scholar
• Weaver C H, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961–3969
   PubMed Web of Science ®Google Scholar
• Haas R, Mohle R, Fruhauf S, et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787–3794
   PubMed Web of Science ®Google Scholar
• Gazitt Y, Tian E, Barlogie B, et al. Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor. Blood 1996; 87: 805–811
   PubMed Web of Science ®Google Scholar
• Brugger W, Bross K J, Glatt M, et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83: 636–640
   PubMed Web of Science ®Google Scholar
• Jacquy C, Soree A, Lambert F, et al. A quantitative study of peripheral blood stem cell contamination in diffuse large-cell non-Hodgkin's lymphoma: one-half of patients significantly mobilize malignant cells. Br J Haematol 2000; 110: 631–637
   PubMed Web of Science ®Google Scholar
• Bierman P J, Sweetenham J W, Loberiza-Jr F R, et al. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation- the Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol 2003; 21: 3744–3753
   PubMed Web of Science ®Google Scholar
• Fouillard L, Laporte J P, Labopin M, et al. Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation- results of a retrospective analysis on 120 patients autografted in a single institution. J Clin Oncol 1998; 16: 2803–2816
   PubMed Web of Science ®Google Scholar
• Lopez M, Lemoine F M, Firat H, et al. Bone marrow versus peripheral blood progenitor cells CD34 selection in patients with non-Hodgkin's lymphoma: different levels of tumor cell reduction. Implications for autografting. Blood 1997; 90: 2830–2838
   PubMed Web of Science ®Google Scholar
• Flinn I W, O'Donnell P V, Goodrich A, et al. Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biol. Blood Marrow Transplant 2000; 6: 628–632
   PubMed Web of Science ®Google Scholar
• Magni M, DiNicola M, Devizzi L, et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96: 864–869
   PubMed Web of Science ®Google Scholar
• Gribben J G, Freedman A S, Neuberg D, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991; 325: 1525–1533
   PubMed Web of Science ®Google Scholar
• Vose J M, Sharp G, Chan W C, et al. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease. J Clin Oncol 2002; 20: 2344–2352
   PubMed Web of Science ®Google Scholar
• Blystad A K, Delabie J, Kvaloy S, et al. Infused CD34 + cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy. Brit J Haematol 2004; 125: 605–612
   PubMed Web of Science ®Google Scholar
• Stewart A K, Vescio R, Schiller G, et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 2001; 19: 3771–3779
   PubMed Web of Science ®Google Scholar
• Abonour R, Scott K M, Kunkel L A, et al. Autologous transplantation of mobilized peripheral blood CD34 + cells selected by immunomagnetic procedures in patients with multiple myeloma. Bone Marrow Transplant 1998; 22: 957–963
   PubMed Web of Science ®Google Scholar
• Press O W, Eary J F, Gooley T, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000; 96: 2934–2942
   PubMed Web of Science ®Google Scholar
• Vose J M, Bierman P J, Enke C, et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 461–467
   PubMed Web of Science ®Google Scholar
• Klingemann H -G, Phillips G L. Immunotherapy after bone marrow transplantation. Bone Marrow Transplant 1991; 8: 73–81
   PubMed Web of Science ®Google Scholar
• Rapaport A P, Meisenberg B, Sarkodee-Adoo C, et al. Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy. Bone Marrow Transplant 2002; 29: 303–312
   PubMed Web of Science ®Google Scholar
• Benyunes M C, Higuchi C M, York A, et al. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial. Bone Marrow Transplant 1995; 16: 283–288
   PubMed Web of Science ®Google Scholar
• Nagler A, Ackerstein A, Or R, et al. Immunotherapy with recombinant human interleukin-2 and recombinant interferon-α in lymphoma patients postautologous marrow or stem cell transplantation. Blood 1997; 89: 3951–3959
   PubMed Web of Science ®Google Scholar
• Collins R H, Jr, Shpilberg O, Drobyski W R, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433–444
   PubMed Web of Science ®Google Scholar
• Khouri I F, Saliba R, Giralt S, et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001; 98: 3595–3599
   PubMed Web of Science ®Google Scholar
• Horwitz S M, Negrin R S, Blume K G, et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic stem cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004; 103: 777–783
   PubMed Web of Science ®Google Scholar